Vol. 58, Issue 6, 1333-1340, December 2000

Decoy Oligodeoxynucleotide Characterization of Transcription Factors Controlling Endothelin-B Receptor Expression in Vascular Smooth Muscle Cells

Andreas H. Wagner, Robert Krzesz,¹ Dingcheng Gao, Christian Schroeder, Marco Cattaruzza, and Markus Hecker

Department of Cardiovascular Physiology, University of Goettingen, Germany (A.H.W., D.G., M.C., M.H.); and Institute of Physiological Chemistry and Pathobiochemistry, University of Mainz, Mainz, Germany (C.S.)

Endothelin-1 is not only a powerful vasoconstrictor but also a potent mitogen for vascular smooth muscle cells (SMC), acting through both the endothelin-A and endothelin-B receptor (ET_B-R). Although vascular SMC are known to express the ET_B-R, its transcriptional regulation has not been studied thus far. Here we demonstrate that the potent inhibitor of nuclear factor B activation, pyrrolidine dithiocarbamate (PDTC; 30-100 µM), induces de novo ET_B-R expression in rat aortic and mesenteric cultured SMC. Electrophoretic mobility shift analyses revealed that besides inhibition of nuclear factor B, PDTC enhances activator protein-1 (AP-1), CCAAT/enhancer-binding protein (C/EBP), and GATA-2 activity in these cells. Preincubation of PDTC-stimulated cells with appropriate decoy oligodeoxynucleotides confirmed the involvement of these three transcription factors, namely that of AP-1, in ET_B-R expression. The stimulatory effect of PDTC on ET_B-R expression was also confirmed functionally by monitoring an enhanced ET-1-induced apoptosis in PDTC-treated cells that was sensitive to the ET_B-R antagonist, BQ788. Taken together, these findings demonstrate that C/EBP, GATA-2, and in particular AP-1 can control ET_B-R expression in vascular SMC. They further support the notion that ET_B-R expression in these cells may play an important role in cardiovascular complications, such as restenosis following angioplasty that in the early phase is characterized by prominent SMC apoptosis.